Researchers found that the vaccine, named ELI-002 2P, could trigger lasting immune responses and may help prevent or delay ...

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

The vaccine would train the immune system to fight cancer-causing mutations, according to new research from UCLA Health.

Zev A. Wainberg, MD, discussed the significance of the AMPLIFY-201 trial, next steps for this vaccine platform, and the signs ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

Researchers recently discovered that an experimental cancer vaccine offers "a promising approach" to preventing cancers from ...

Cancer rates in 2025 are predicted to exceed the previous year's statistics, with one-in-three men and women both at risk of contracting the disease.

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

A new study reveals promising results for a vaccine targeting colorectal and pancreatic cancers. Researchers from the ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

Phase 1 trial of a pancreatic cancer vaccine targeting mutant KRAS shows strong immune responses, extended survival, and ...

Researchers found patients with pancreatic cancer and bowel cancer survived more than two years after receiving the vaccine ...